MAIA Biotechnology partners with Roche for cancer treatment studies

 MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biotech company with a market capitalization of $50.31 million, has entered into a clinical master supply agreement with Roche to investigate the combination of MAIA’s telomere-targeting agent ateganosine (THIO) with Roche’s checkpoint inhibitor atezolizumab (Tecentriq) for treating multiple hard-to-treat cancers, according to a press release statement. 

The agreement will support future studies examining the potential efficacy of combining these treatments. Preclinical studies have shown ateganosine to be "highly synergistic and effective" when used with Roche’s anti-PD-L1 agent, according to Vlad Vitoc, M.D., MAIA’s Chairman and CEO. 

Ateganosine is a first-in-class investigational telomere-targeting agent currently in clinical development for non-small cell lung cancer (NSCLC). The compound works by inducing telomerase-dependent telomeric DNA modification, triggering DNA damage responses and selective cancer cell death.

The treatment is being developed as a second or later line of treatment for NSCLC patients who have progressed beyond standard checkpoint inhibitor regimens.

https://www.investing.com/news/company-news/maia-biotechnology-partners-with-roche-for-cancer-treatment-studies-93CH-4101314